Doximity's AI Paradox: Record User Growth Meets Shrinking Profits

SAN FRANCISCO, CA – August 06, 2026 – In the world of technology, progress often comes with a hefty price tag. Doximity, the digital network often called the 'LinkedIn for doctors,' just sent a clear signal about the cost of leading the AI race in medicine. The company’s latest quarterly report presents a fascinating paradox: while user engagement and adoption of its new AI tools are skyrocketing, its profitability and cash flow have taken a significant hit. It’s a classic tech narrative of investing heavily today for a promised payoff tomorrow, leaving investors and industry watchers to grapple with a fundamental question: Is this the necessary cost of innovation, or a sign of unsustainable spending?

For a company that commands a network of over 85% of U.S. physicians, the first quarter of its fiscal 2027 was a tale of two starkly different reports. On one hand, Doximity celebrated a 7% year-over-year revenue increase to $156.6 million, beating its own guidance. CEO Jeff Tangney proudly announced “another quarter of record engagement,” citing impressive growth metrics that suggest its platform is becoming more indispensable to clinicians than ever. Yet, on the other hand, the financial statements told a story of contraction. Net income plummeted to $24.3 million from $53.3 million a year prior, and key profitability metrics like adjusted EBITDA and free cash flow fell by 6% and 34%, respectively. This divergence highlights a deliberate strategic pivot, with the company betting its future on becoming the essential AI-powered assistant for every doctor in the country.

A Tale of Two Reports

The positive momentum is undeniable. According to Tangney, the company saw “workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter.” These aren't just vanity metrics; they represent deepening integration into the daily routines of medical professionals. Doctors, nurse practitioners, and physician assistants are increasingly using Doximity’s suite of tools for everything from secure messaging and virtual visits to the company’s new AI-powered features. The tenfold increase in users of its AI Scribe tool in July alone underscores the voracious appetite for technologies that can alleviate the crushing burden of administrative work in healthcare.

But this surge in activity is directly linked to the concerning dip in financial performance. The balance sheet reveals a company consciously sacrificing near-term margins for long-term market capture. Net income margin was more than halved, dropping to 15.5% from 36.5% a year ago. Adjusted EBITDA margins, a key measure of operational efficiency that strips out certain expenses, also compressed, falling from a robust 54.7% to 47.7%. It’s a clear trade-off, and the details reveal just how heavily Doximity is investing in its technological transformation.

The High Cost of AI Dominance

Digging into Doximity’s financial statements reveals that fiscal 2027 has been designated an “AI investment year.” This isn't just rhetoric; it’s a strategy backed by a significant reallocation of capital. The primary driver of shrinking profits is a sharp increase in operating expenses. Research and development (R&D) costs swelled by nearly 44% year-over-year to $38.5 million, while sales and marketing expenses climbed 24% to $45.0 million. This spending spree is fueling the development and rollout of tools like Doximity Ask, the company's clinical AI assistant.

Even the cost of generating revenue is rising. The company’s non-GAAP gross margin, which reflects the profitability of its core services, tightened to 88% from 91% a year ago. Management attributes this directly to higher AI compute expenses needed to handle the greater-than-expected use of its AI tools. Furthermore, stock-based compensation surged to $37 million for the quarter, representing 23% of total revenue. A significant portion of this is tied to grants awarded to the AI-focused R&D team, signaling a clear effort to attract and retain top talent in a hyper-competitive field. In essence, Doximity is paying a premium in both cash and equity to build its AI moat.

Validating the Bet: NOHARM and a Growing Client Roster

For Doximity, the justification for this spending comes from powerful external and internal validation. The company’s AI assistant, Doximity Ask, was recently named the top-performing U.S.-based model in the NOHARM benchmark, an independent study from a clinical AI research team at Stanford and Harvard. The benchmark, which assesses the safety and error rates of clinical AI, found Doximity Ask had the lowest error rate (4.8%) among 24 different models. In a field where trust and safety are paramount, such a credential is invaluable for driving physician adoption.

This technical validation is already translating into commercial success. Even before recognizing any significant revenue from the product, Doximity has signed up 165 health systems as AI clients, including prestigious institutions like Northwestern, Penn Medicine, and the University of Michigan. This early traction suggests that hospitals and large medical groups see a clear return on investment in Doximity's AI tools. A key insight from management provides the financial logic behind the push: the company reportedly earns “10 times more per AI search than it costs to run one.” This potential for highly profitable, scalable revenue is the prize Doximity is chasing, and it appears investors are willing to wait for it.

Navigating the Financial Headwinds

Despite the pressure on profits and cash flow, Doximity’s financial foundation remains solid. The company ended the quarter with $688 million in cash and marketable securities and no debt. This strong liquidity position gives it the runway to see its AI investment through. The company even demonstrated confidence by repurchasing $91.6 million of its own stock during the quarter. The market, in turn, has responded with surprising optimism. Following the earnings release, Doximity’s stock surged, indicating that investors are buying into the long-term vision.

This confidence is bolstered by the company’s outlook. While guidance for the upcoming second quarter suggests muted year-over-year growth due to a tough comparison period, Doximity raised its revenue forecast for the full fiscal year to a range of $671 million to $681 million. This implies an expectation that AI-related revenue will begin to ramp up significantly in the second half of the year. The current financial strain, therefore, is being framed not as a problem, but as a calculated and temporary phase in a much larger strategic play to cement its role as the indispensable digital partner for American medicine.